C
Cheilonda Johnson
Researcher at Johns Hopkins University School of Medicine
Publications - 25
Citations - 964
Cheilonda Johnson is an academic researcher from Johns Hopkins University School of Medicine. The author has contributed to research in topics: Interstitial lung disease & Dermatomyositis. The author has an hindex of 13, co-authored 22 publications receiving 615 citations. Previous affiliations of Cheilonda Johnson include Johns Hopkins University & University of Pennsylvania.
Papers
More filters
Journal ArticleDOI
A longitudinal cohort study of the anti-synthetase syndrome: increased severity of interstitial lung disease in black patients and patients with anti-PL7 and anti-PL12 autoantibodies.
Iago Pinal-Fernandez,Maria Casal-Dominguez,Julio Huapaya,Jemima Albayda,Julie J. Paik,Cheilonda Johnson,Leann Silhan,Lisa Christopher-Stine,Andrew L. Mammen,Sonye K. Danoff +9 more
TL;DR: Different AsyS autoantibodies are associated with phenotypically distinct subgroups within the ASyS spectrum, characterized by more severe lung involvement, whereas anti-Jo1 is associated with more severe muscle involvement.
Journal ArticleDOI
Antinuclear Matrix Protein 2 Autoantibodies and Edema, Muscle Disease, and Malignancy Risk in Dermatomyositis Patients
Jemima Albayda,Iago Pinal-Fernandez,Wilson Huang,Cassie A. Parks,Julie Paik,Livia Casciola-Rosen,Sonye K. Danoff,Cheilonda Johnson,Lisa Christopher-Stine,Andrew L. Mammen +9 more
TL;DR: It was observed that DM patients with autoantibodies recognizing the nuclear matrix protein NXP‐2 often presented with especially severe weakness, and the aim of this study was to characterize the clinical features associated with anti–NXP–2 autoantibia.
Journal ArticleDOI
Management of Myositis-Related Interstitial Lung Disease
TL;DR: This review covers the existing evidence on the pharmacologic and nonpharmacologic management of myositis-related ILD, highlighting the lack of randomized controlled data to guide treatment.
Journal ArticleDOI
Assessment of Mortality in Autoimmune Myositis With and Without Associated Interstitial Lung Disease.
Cheilonda Johnson,Iago Pinal-Fernandez,Radhika Parikh,Julie Paik,Jemima Albayda,Andrew L. Mammen,Andrew L. Mammen,Lisa Christopher-Stine,Sonye K. Danoff +8 more
TL;DR: The results suggest that ILD remains an important and significant source of mortality in patients with inflammatory myopathies and as such should be screened for and treated aggressively.
Journal ArticleDOI
Long-Term Treatment With Azathioprine and Mycophenolate Mofetil for Myositis-Related Interstitial Lung Disease
Julio Huapaya,Leann Silhan,Iago Pinal-Fernandez,Maria Casal-Dominguez,Cheilonda Johnson,Jemima Albayda,Julie J. Paik,Abanti Sanyal,Andrew L. Mammen,Andrew L. Mammen,Lisa Christopher-Stine,Sonye K. Danoff +11 more
TL;DR: In M-ILD, AZA treatment was associated with improved FVC%, DLCO%, and prednisone dose, and after 36 months, patients treated with AZA used a lower prednis one dose than those treated with MMF.